The present invention relates in general to the field of vaccines and, more particularly, to compositions and methods for the production of dendritic cells generated using dendritic cell activation factors and loaded with heat-treated and killed cancer cells.
Without limiting the scope of the invention, its background is described in connection with cancer cell vaccines.
Numerous methods for the isolation, characterization and induction of immune responses have been developed. For example, in U.S. Pat. No. 6,821,778, issued to Engleman, et al., certain methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells are taught. Briefly, methods of using human dendritic cells to present antigens for the induction of antigen-specific T cell-mediated immune responses are taught. In particular, the disclosure includes the isolation of dendritic cells from human blood, exposing the cells to antigens, co-culturing the antigen-pulsed dendritic cells with gamma/delta-T cell receptor-positive-T cells (gamma/delta-TCR+T cells) obtained from unprimed or weakly primed individuals for the stimulation of antigen-specific T cell proliferative and cytotoxic activities. The dendritic cell antigen presentation system described therein is said to have wide range of applications, e.g., activation and expansion of large numbers of antigen-specific major histocompatibility complex-unrestricted T cells for use in adoptive cellular immunotherapy against infectious diseases and cancer.
Yet another example of dendritic cell manipulation is taught in U.S. Pat. No. 6,652,848, issued to Gong, et al., which teaches dendritic cell hybrids. Gong teaches immunostimulatory compositions that contain fused cells formed by fusion between dendritic cells and non-dendritic cells, methods of using these compositions, and methods of generating dendritic cell hybrids.
U.S. Pat. No. 6,602,709, issued to Albert, et al., includes methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells. The disclosure teaches methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. The disclosure is also said to provide assays for evaluating the activity of cytotoxic T lymphocytes. Briefly, antigens are targeted to dendritic cells by apoptotic cells, which may be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells are primed by the apoptotic cells are said to be capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.
U.S. Pat. No. 6,475,483, issued to Steinman, et al., disclosed methods for in vitro proliferation of dendritic cell precursors and their use to produce immunogens for treating autoimmune diseases. The disclosure is said to teach methods for producing proliferating cultures of dendritic cell precursors is provided, as well as methods for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens that consist of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.
The present invention includes compositions and methods for inducing immune responses that are coordinated and regulated by dendritic cells (DCs)1,2. DCs are present in peripheral tissues, where they are poised to capture antigens. These antigens are subsequently processed into small peptides as the DCs mature and move towards the draining secondary lymphoid organs3. There, the DCs present the peptides to naive T cells, thus inducing a cellular immune response, involving both T helper 1 (Th1) type CD4+ T cells and cytolytic CD8+ T cells. DCs are important in launching humoral immunity through their capacity to activate naïve4 and memory5 B cells. DCs can also activate natural killer (NK) cells6 and NKT cells7. Because of their many capabilities, DCs are able to conduct all elements of the immune orchestra and therefore represent a fundamental target and tool for vaccination.
Ex vivo-generated and antigen-loaded DCs have recently been used as vaccines to improve immunity8. Numerous studies in mice have shown that DCs loaded with tumor antigens can induce therapeutic and protective anti-tumor immunity9. The immunogenicity of antigens delivered on DCs has been shown in patients with cancer8 and chronic HIV infection10, thus providing a “proof-of-principle” that DC vaccines can be effective. The identification of distinct DC subsets that induce distinct types of immune response and the role of DCs in the expansion of cells with regulatory/suppressor function provide novel parameters to be tested for design of better vaccination strategies for patients with cancer.
The present invention includes compositions and methods for the activation and presentation of antigen by antigen presenting cells. More particularly, the present invention include a method of making a composition for treating cancer by activating one or more dendritic cells that present one or more cancer antigens and induce T cell activation through incubation of the one or more dendritic cells with one or more cancer cells that are heat shocked and subsequently killed. The method may also include the step of pulsing the antigen presenting cells with an antigen comprising the remains of one or more cancer cells that are heat shocked and subsequently killed under conditions that induce T-cell activation. The method may also include the step of storing cryogenically the one or more antigen presenting cells that have been pulsed with the cancer cells that are heat shocked and subsequently killed. The one or more antigen presenting cells may be dendritic cells that present one or more cancer specific antigen obtained after heat shock and killing of the cancer cells to one or more CD8+ or CD4+ T cells. The antigen presenting cells may be dendritic cells, monocytes, autologous cells, heterologous cells, cell fragments and/or a combination thereof.
In certain examples, the one or more antigen presenting dendritic cells include one or more dendritic cells, e.g., monocytes that have been activated with IFNα. The antigen presenting cells may be derived from monocytes cultured with GM-CSF and IFNα. Examples of antigen presenting cells may be antigen presenting dendritic cells that are expressing one or more melanoma cell-derived heat shock proteins, e.g., heat inactivated melanoma cells derived from a patient. Alternatively, the one or more heat inactivated melanoma cells may be of the same basic cell type or even cancer cell type as the patient. In certain embodiments, the cancer cells are Colo829 melanoma cells. In one example, the cancer cells are established cancer cell lines, e.g., cultured melanoma cells, e.g., Mel-2, Mel-3, Mel-4, Mel-6 and/or Mel-9 cells or a combination thereof.
In certain embodiments, the cancer cells are treated by heating for about 0.5 to 4 hours at between about 38° C. and about 46° C. The cancer cells may be killed by gamma-irradiation for about 0.5 hours at about 160 Gy and/or killed by the heating, freeze-thaw cycles, French press, shearing, direct or indirect compression, freezing, cracking, drying, chemical exposure and biological agents that cause cell death (other than apoptosis) and the like. The present invention also includes the addition of one or more pulsed antigen presenting cells, which may include, enucleated dendritic cells and one or more heat treated cancer cells capable of inducing T cell activation, pulsed with a heat-shocked cells that is subsequently killed and processed for presentation. In certain embodiments, the composition is injected subcutaneously in at least one site selected from the group consisting of an anterior thigh, or an upper arm.
Non-limiting examples of cancer cells for heat-tretment and killing to make an antigen for presentation may include cells derived from, e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, Kaposi's sarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdosarcoma, colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, myeloma, lymphoma, and leukemia.
The cancer that may be used to pulse the cells and/or that is the subject of treatment may include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, Kaposi's sarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdosarcoma, colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, myeloma, lymphoma, and leukemia.
Yet another embodiment is a method of making a dendritic cell that presents cancer antigens by differentiating one or more monocytes into one or more dendritic cells and loading the one or more dendritic cells with an antigen presenting composition that includes one or more cancer cells that are heat shocked and subsequently killed, wherein the one or more dendritic cells are under conditions that cause the one or more dendritic cells to present one or more antigens in the composition.
Another method of the present invention is a method of making an IFNα dendritic cell that presents melonoma antigens by isolating one or more monocytes from a patient suspected of having cancer; maturing the one or more monocytes into one or more IFNα dendritic cells; and loading the one or more IFNα dendritic cells with an antigens presenting composition having one or more cancer cells that are heat shocked and subsequently killed, wherein the loaded one or more IFNα dendritic cells are capable of inducing T cell activation and under conditions that allow the one or more IFNα dendritic cells to present one or more antigens in the composition.
The present invention also includes a cancer specific vaccine capable of inducing T cell activation, includes a pharmaceutically effective amount of one or more dendritic cells activated to present antigen wherein the dendritic cells present one or more antigens that are one or more cancer cells that have been heat shocked and killed after the heat shock. In one embodiment, the cancer cells have been heat shocked or treated and killed (but are not apoptotic) at the time of killing. Another example of the present invention is a melanoma-specific vaccine capable of inducing T cell activation that includes a pharmaceutically effective amount of one or more monocytes exposed to IFNα and that have matured into dendritic cells (IFNα dendritic cells) loaded and presenting an antigen that is heat shocked and subsequently killed melanoma cells, wherein the one or more IFNα dendritic cells are incubated under conditions that promote the presentation of the one or more melanoma to T cells. The vaccine may be made by a method that also includes the step of adding a pulsed preparation for T-cell activation comprising one or more pulsed enucleated antigen presenting cells.
Yet another method of the present invention includes a method of treating a patient suspected of having cancerous cell growth by loading one or more cancer antigens on an activated dendritic cell under conditions that include antigen presentation and that induce T-cell activation, wherein the cancer antigens include cancer cells that have been heat shocked and subsequently killed; and administering to the patient in need thereof the one or more dendritic cells that present one or more cancer antigens to activate T cells.
Yet another method of the present invention includes a method of treated a patient suspected of having cancer by isolating and maturing one or more monocytes with IFNα and GM-CSF into dendritic cells matured with these cytokines, loading the one or more dendritic cells capable of inducing T cell activation with a composition with one or more heat treated cancer cells that are heat shocked and subsequently killed to form one or more antigen presenting dendritic cells; and administering the one or more antigen presenting dendritic cells to the patient in need thereof.
For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures and in which:
DCs are loaded with unheated (cold) or heated (hot) killed melanoma cells, either HLA-A*0201+ Me290 or HLA-A*0201 negative Skmel 28. After 2 stimulations, HLA-A*0201+ CD8+T cells are boosted with peptide pulsed DCs. Flow cytometry staining with MAGE 10 tetramer. % of tetramer binding CD3+T cells. Two studies.
While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.
To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.
Abbreviations. GM-CSF: Granulocyte macrophage-colony stimulating factor; IFN alpha: Interferon alpha; LPS: lipopolysaccharide; TNF: Tumor necrosis factor; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NPD: Non-progressive disease; NED: No evidence of disease; MDCs: Monocyte derived dendritic cells; CTLs: Cytotoxic T lymphocytes; NK cells: Natural Killer Cells; NKT cells: Natural Killer T cells; ND: Not done; NT: Not tested; TBD: To be determined.
Cancer immunotherapy. There are numerous strategies for improving a patient's resistance to cancer. Among these strategies are 1) non-specific activation of the immune system with microbial components or cytokines; 2) antigen-specific adoptive immunotherapy with antibodies and/or T cells; and 3) antigen-specific active immunotherapy (vaccination). The major limitation of antibodies is that target proteins must be expressed on the cell surface as opposed to targets for T cells that can be intracellular proteins whose peptides are presented on the cell surface in complexes with MHC molecules11. The identification of defined tumor antigens in humans12,13 prompted the development of adoptive T-cell therapy. Yet, vaccination remains the most attractive strategy because of its expected inducement of both therapeutic T-cell immunity (tumor-specific effector T cells) and protective T cell immunity (tumor-specific memory T cells that can control tumor relapse)14-16.
Numerous approaches for the therapeutic vaccination of humans with cancer have been developed, including: autologous and allogeneic tumor cells (which are often modified to express various cytokines), peptides, proteins and DNA vaccines8,16-19. All of these approaches rely on a random encounter of the vaccine with host DCs. If the vaccine antigen does not result in an encounter with DCs an immune response cannot occur. In addition, an inappropriate encounter with either non-activated DCs or the “wrong” subset of DCs can lead to silencing of the immune response20. Both of these scenarios may explain some of the shortcomings in current cancer vaccines. Furthermore, it is not known how tumor antigens need to be delivered to DCs in vivo in order to elicit an appropriate immune response. Hence, there is a need for studies based on ex vivo-generated autologous DCs that are loaded with tumor antigen under controlled conditions which might allow the establishment of parameters for optimal vaccination against cancer. Clinical studies using DCs as vaccines were facilitated by the discovery of methods to generate large numbers of autologous DCs ex vivo21-23. Parameters that should be considered to improve the efficacy of DC vaccinations in cancer include: DC related factors; host-related factors; and a combination of DC vaccines with other therapies. Two DC related parameters, i.e., a novel DC subset and a novel strategy to load tumor antigens are briefly discussed below.
Parameters of DC vaccines. DC subsets: The discovery that GM-CSF and IL-4 can differentiate monocytes into immature DCs22-24 has allowed major progress in our understanding of DC biology and function. Several institutions have used IL4-DCs as vaccines8 following pioneering clinical studies in patients with metastatic melanoma by Nestle, et al.25 (using tumor-lysate-loaded DCs) and by Schuler and colleagues26 (using melanoma-peptide-loaded DCs). However, recent discoveries point to new alternatives to the classical way of generating DCs. For example, melanoma-peptide-pulsed IL15-DCs are more efficient than IL4-DCs for the induction of antigen-specific CTL differentiation in vitro, whereas their ability to stimulate CD4+T cells is comparable27. Also, IFN-alpha-DCs generated in three-day cultures have been found to be efficient for the induction of specific immunity28. Thus, the immunogenicity of these distinct DC vaccines warrants testing in vivo in clinical studies.
Antigen loading. Loading MHC class I and MHC class II molecules on DCs with peptides derived from defined antigens is the most commonly used strategy for DC vaccination15,29. Although this technique is important for “proof of concept” studies, the use of peptides has limitations for further vaccine development: restriction to a given HLA type; the limited number of well characterized tumor-associated antigens (TAA); the relatively rapid turnover of exogenous peptide-MHC complexes resulting in comparatively low antigen presentation at the time the DC arrive into draining lymph node after injection; and, the induction of a restricted repertoire of T-cell clones, thus limiting the ability of the immune system to control tumor antigen variation. Many of these peptides may differ from naturally processed epitopes. Thus, loading DCs with total antigen preparations and allowing “natural” processing and epitope selection is expected to improve efficacy and allow the generation of a diverse immune response involving many clones of CD4+T cells and CTLs. All of these strategies load DCs with recombinant proteins, exosomes30, viral vectors31, plasmid DNA, RNA transfection32, immune complexes33 and antibodies specific for DC surface molecules15,34.
Another technique involves exploiting the capacity of DCs to present peptides from phagocytosed dead tumor cells on MHC class I molecules (as well as class II molecules). This is known as cross-priming35,36. Indeed, DCs cultured with killed allogeneic melanoma, prostate or breast cancer cell lines prime naive CD8+T cells against tumor antigens in vitro36,37. 20 patients with metastatic melanoma have been vaccinated at BIIR to date with autologous monocyte-derived DCs previously exposed to a killed allogeneic melanoma cell line (8 vaccines on a monthly basis). Vaccination has proved to be safe (no autoimmunity or other adverse events) and has led to the induction of melanoma-specific T cell immunity. In two patients, a long-lasting tumor regression has been observed. These results warrant larger clinical studies to prove the efficacy of the vaccine preparation methodology.
GM-CSF and IFN alpha induced dendritic cell vaccine. Several recent findings in IFN biology reactivated immunologists' interest in this family of molecules. These findings include 1) the demonstration that plasmacytoid dendritic cells (pDCs, a subset of human and murine DCs) promptly secrete large amounts of type I IFNs in response to viral signals74; 2) the abilities of IFN alpha/beta to activate immature myeloid DCs75 and to induce the differentiation of monocytes into DCs28,76; 3) the activity of IFN alpha/beta in the generation of memory CD8+T cells77,78 and the stimulation of antibody responses5,79, 80; 4) the central role of IFN alpha/beta in the pathogenesis of Systemic Lupus Erythematosus81, 82; 5) the secretion of low levels of IFN alpha/beta to rev up the immune system, as illustrated by the essential role of IFN alpha/beta in the LPS signaling and the development of septic shock.83
It was recently recognized by the present inventors that IFN alpha is essential in launching human humoral responses specific to Influenza virus.5 This raised a potential that IFN alpha could possibly enhance the generation of CTLs, most particularly those directed against tumor antigens.
IFN-DCs efficiently activate cytolytic CD8+T cells: The biological properties of DC vaccine generated from monocytes by culturing them with GM-CSF and IFN alpha (IFN-DC) were compared with two previous products manufactured, viz., DC vaccines made by culturing monocytes with GM-CSF and either TNF (TNF-DCs) or IL-4 (IL4-DCs). Allogeneic CD8+T cells were cultured for 5 days with each DC subset, then re-purified by cell sorting and analyzed by flow cytometry. Strikingly, results showed that IFN-DCs can induce CD8+T cells with considerably higher expression of cytolytic T cell molecules such as Granzymes A and B (
IFN-DCs respond differentially to maturation stimuli: To further characterize the role of IFN-DCs in cancer vaccines, cytokine biosignatures were analyzed in IFN-DCs exposed in vitro to various activation signals including CD40 ligand, lonomycin, and TLR ligands such as LPS (TLR4), poly I:C (TLR3) and zymosan (TLR2). IFN-DCs, generated by culturing purified monocytes with GM-CSF and recombinant human IFN alpha 2a, were exposed to various stimuli and cytokine/chemokine secretion into culture supernatants and measured at different time points using Multiplex cytokine beads (Luminex). Preliminary analysis demonstrated that the profile of secreted cytokines does not change significantly over 48 hrs of exposure (not shown). As shown in
IFN-DCs uniquely secrete IL-7, a T cell growth factor: Upon single cytokine analysis, it was observed that IFN-DCs spontaneously secrete detectable levels of IL-7 (
IFN-DCs efficiently cross-prime tumor-specific CTLs: To determine whether IFN-DCs were indeed more powerful in stimulating CTLs, DCs were loaded with killed melanoma or breast cancer cells and then used to prime purified CD8+T cells in 2 culture cycles. IFN-DCs were observed to be more efficient than IL4-DCs in priming CTLs that have the capacity to kill cancer cells (
Thus, IFN-DCs have been shown to be highly efficient at cross-priming naive CD8+T cells to differentiate into CTLs specific for tumor antigens. This finding has potentially high therapeutic implications for cancer vaccines. Thus, IFN-DCs are more efficient in the induction of tumor specific immunity which warrants further testing of their in vivo activity in patients in the clinical setting.
Generation of highly immunogenic killed tumor cells for loading DC vaccines. The use of hyperthermia in cancer therapy, either alone or as an adjuvant for radiotherapy, has been an object of clinical interest for many years84. Hyperthermia seems to be particularly effective in combination with radiotherapy and/or radio-immunotherapy (reviewed in 85 ,86). The molecular mechanism by which hyperthermia leads to radiosensitization is not clear, however activation of early response genes and heat shock factors (HSFs) and subsequently heat shock proteins (HSPs) are likely to play a role in this occurence87. HSPs constitute a superfamily of distinct proteins, which are operationally named according to their molecular weight, e.g. hsp70. Most HSPs are expressed constitutively and are further induced under stress conditions, including temperature increase. HSPs are considered as molecular relay line that chaperones the peptides from their generation in the cytosol to their binding to MHC class I in the ER88,89. HSP70, HSP60 and GP96 have been recently established as immune adjuvants for cross-priming with antigenic proteins or peptides90,91. In this process, reconstituted hsp70 or gp96-peptide complex are internalized by antigen presenting cells (APCs) including DCs, through receptor-mediated endocytosis via CD9192, CD4093, LOX-194 or TLR2/495. Thus, the present inventors recognized that hyperthermia could enhance cross-priming and thereby contribute to the manufacture of a vaccine which would allow enhanced tumor regression.
Heated Melanoma Cells. The goal of current research has been to create altered tumor cell bodies that are highly immunogenic and could be used to load DCs for vaccination purposes. Therefore, having established the premise that melanoma cell lines overexpressing HSP70 are indeed more immunogenic (not shown), the focus of this investigation now shifted to the development of a means to increase HSP expression in clinical grade conditions. Thus, whether heat-treatment of melanoma cells could increase immunogenicity of loaded DCs was determined.
Heat treatment of melanoma cells increases HSP70: Melanoma cell lines were incubated in the for 4 hrs at 42° C. (heat shock). The analysis of HSPs expression by ELISA (not shown) or by intracellular staining (
DCs loaded with heat-treated melanoma bodies rapidly yield CTLs able to kill melanoma cells: Unloaded DCs (CTL 1), DCs loaded with control melanoma bodies (CTL 2) and DCs loaded with heat-shocked melanoma bodies (CTL 3) were cultured for 2 weeks with purified naive CD8+T cells. T cell cultures were restimulated once (a total of two stimulations) and were supplemented with soluble CD40 ligand and low dose IL-7 (10 U/ml, all culture) and IL-2 in the second week (10 U/ml). T cells were analyzed 7 days after restimulation (total 14 days of culture).
It was noted that T cells cultured with DCs loaded with heat- treated Me275 melanoma bodies but not control bodies, were able to kill Me275 cells (
DCs loaded with heat shocked melanoma bodies rapidly yield melanoma-specific CTLs: Na ive CD8+T cells primed with heat-treated melanoma bodies can specifically and efficiently kill T2 cells loaded with four melanoma peptides but not PSA peptide. Melanoma cell lines were also destroyed, but the breast cell line MCF7 and K562 cells were unaffected (
Tetramer binding analysis confirmed this finding and showed that up to 0.4% of CD8+T cells were specific for MART-1 (
Heat treatment of melanoma cells enhances transcription of tumor antigens. The original hypothesis that the enhanced cross-priming would be due to enhanced expression of Heat Shock Proteins was found to be consistent with studies that demonstrated purified HSP70, HSP60 and GP96 act immune adjuvants for cross-priming with antigenic proteins or peptides90,91. After Microarray analysis of control and HSP70 transduced Sk-Mel28 cells, however, an increased transcription of several tumor antigens including MAGE-A10 (not shown) was observed. Therefore, 12 genes encoding different members of MAGE tumor antigen family were measured by real-time PCR expressions. These antigens included MAGE-B3, MAGE-A8 (
Therefore, HLA-A*0201 restricted peptides derived from MAGE-A8 and MAGE-A10 were identified and analyzed to determine whether DCs loaded with heat-treated bodies could prime CTLs specific for these two epitopes. As shown in
Thus, hyperthermia-increased transcription of tumor antigens could contribute to enhanced cross-priming. DCs loaded with heat-treated killed melanoma bodies induce autologous naive CD8+ or CD4+T cells to produce increased levels of IFN gamma and decreased levels of IL-10 Regulatory/suppressor T cells are considered to be one of the major obstacles in successful vaccination of patients against their cancer. As shown in
The present invention includes autologous dendritic cells derived from monocytes with GM-CSF and IFN alpha and loaded with killed allogeneic Colo829 melanoma cells. Autologous dendritic cells are manufactured from monocytes separated by elutriation from peripheral blood mononuclear cells obtained by apheresis. Monocytes are cultured in a closed system in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF) and Interferon alpha (IFN alpha, loaded with heated and killed allogeneic COLO 829 tumor cells and cryopreserved. Vaccine is stored in liquid nitrogen (vapor phase).
Dendritic cells are manufactured from the apheresis product which is processed to isolate monocytes using the Elutra system (Gambro BCT). Monocytes are transferred from elutriation bag into cultures bags (100 ml volume each) and cultured at 1×106/1 ml volume for 72 hours. In this example, the culture media included serum-free media supplemented with recombinant human GM-CSF (100 ng/ml; Berlex) and Interferon alpha 2b (500 IU/ml; Schering Plough). The skilled artisan, however, would know to titrate the amounts, timing and length of exposure of the cells to the GM-CSF and/or the Interferon alpha to maximize the activation. After initial 24 hours of culture, the vaccine is loaded with killed Colo829 cells. After total of 72 hours culture, dendritic cells are harvested, medium and cytokines are washed out with normal saline. The cells are re-suspended in autologous serum containing 10% DMSO and 10% Plasmalyte, and distributed into cryo-vials at 30×106 cells/vial. The cryovials are frozen using an automated rate controlled freezer and stored in liquid nitrogen (vapor phase).
Isolation. Apheresis—Collect PBMC. Autologous peripheral blood mononuclear cells are obtained by apheresis using a COBE SPECTRA™.
Elutriation—Isolate monocytes. Monocytes are then isolated from the peripheral blood mononuclear cells on a GAMBRO BCT ELUTRA™. The Elutra system is a semi-automatic, closed system centrifuge that uses continuous counter-flow elutriation technology to separate cells into multiple fractions based on size and density. The Elutra system's intended application is monocyte enrichment. The system automatically collects 5 fractions of cells based on size and density. Fraction 5 contains an enriched monocyte population (˜90% purity, n=7 healthy volunteers apheresis) which is used for dendritic cell vaccine manufacture.
Culture—The bag containing Fraction 5 is centrifuged and the buffered saline is expressed off and discarded. The cells are resuspended in CellGenix DC culture medium and a sample is removed for cell count, viability and phenotype. Once the number of monocytes is determined, the cells are diluted to a concentration of 1×106 monocytes/mL and sterile connected to AFC VueLife culture bags. Cytokines GM-CSF (Leukine®) (Berlex Inc.) at a concentration of 100 ng/mL and IFN alfa-2b (INTRON A) (Schering-Plough Corp.) at a concentration of 500 IU/mL are added and the cells are placed in a 37° C. 5% CO2 incubator for culture.
Loading—24 hours after culture initiation, killed tumor cells (COL0829) are added as a source of antigen as well as second dose of GM-CSF and IFN alfa-2b. The killed COL0829 is prepared in batches using gamma irradiation, tested for sterility and inability to proliferate as measured by tritiated thymidine incorporation, frozen at a concentration of 50×106/mL with 10% DMSO in cryovials, and stored in vapor phase nitrogen. An appropriate number of cryovials are thawed so that the DC are loaded 1 killed tumor cell per 2 dendritic cells. The killed COL0829 are washed with culture medium 3 times and added to the culture bags in a small volume.
Dendritic Cell Harvest. 72 hours after culture initiation, the cells are harvested and the vaccine is cryopreserved. The culture bags are centrifuged, the supernatant is expressed and the cells are washed 3 times with normal saline. Washing consists of connecting a bag of normal saline to the culture bag, resuspending the cells in the normal saline, centrifuging the culture bag, and expressing the normal saline into a waste collection bag. After the third wash, the cells are resuspended in Plasmalyte which is the freezing solution diluent. A sample is removed for cell count and viability.
Rate controlled freezing—The vials are frozen using a rate controlled freezer. The vials are placed in a freezing chamber and liquid nitrogen enters the chamber through an electronic solenoid valve. Since vaporization is almost instantaneous, controlling the rate at which liquid nitrogen enters the chamber directly controls the rate at which heat is absorbed and removed from the freezing chamber and its contents.
Cryopreservation. The cells are cryopreserved at a concentration of 30×106 cells/mL. Once the cell number is determined the cells are diluted to 2× the final concentration with autologous serum. A bag of freezing solution containing a volume equal to the cell volume is prepared. The freezing solution is autologous serum with 20% DMSO and 20% plasmalyte. Working rapidly, the freezing solution is added to the cell bag and the cells are transferred to labeled cryovials. The final concentration of DMSO is 10%. The cryovials are frozen using an automated rate controlled freezer at 1° C./min and stored in vapor phase nitrogen.
Storage—The cryovials are transferred from the rate controlled freezer to a liquid nitrogen tank for long term storage. Inventory control is maintained in a database by GMP trained personnel.
Stability of Final Dosage Form of the Active Pharmaceutical Ingredient. Description: Vials containing 1 mL of cryopreserved cells were quickly thawed at 37° and immediately drawn into a syringe containing 9 mL of sterile normal saline (the condition in which cells will be thawed at the clinical site immediately prior to injection) . The normal saline was either at room temperature or 4° C. (refrigerated). The cells were then evenly distributed among 6 tubes and kept at either room temperature or refrigerated. The diluted cells were then assayed at various time points.
Acceptable results for lot release are at least 50% recovery of viable cells and at least 50% viability at 15 min after thaw at room temp. Release testing is performed on three vials obtained at the beginning (1st), in the middle (2nd), and in the end (3rd) of the freezing process.
Frozen vaccine characterization. To further characterize frozen vaccine, beyond viability and capacity to stimulate MLR with CD4+T cells as described above, one or more of the following may be analyzed: (1) morphology and phenotype; (2) cytokine secretion; and/or (3) capacity to induce autologous CD8+T cell differentiation.
IFNα-DCs were generated in culture bags either unloaded or loaded with killed Colo829 cells, frozen and stored at −80° C. for 1, 2 and 3 weeks. Frozen cells were thawed at weeks 1, 2 and 3 and their morphology was assessed by Giemsa staining. As shown in
Upon interaction with T cells, DCs secrete cytokines that regulate T cell differentiation. Therefore, we assessed cytokines secreted by frozen/thawed IFN-DCs (either unloaded or loaded with killed Colo829 cells) when exposed to soluble CD40 ligand to replace T cell signal. Supernatants were assessed after 6 and 24 hrs culture using Multiplex Cytokine Analysis (Luminex). The three major cytokines secreted at levels >lng/ml included IL-8 (˜10ng/ml), IL-6 and MIP1 alpha. As expected from our pre-clinical studies, IFN-DCs secreted IL-7 (
The ultimate parameter of a DC vaccine, is its capacity to present tumor antigen to autologous CD8+T cells and induce their differentiation. Thus, frozen/thawed HLA-A*0201+IFN-DCs were stimulated for 24 hrs with LPS (5 or 10 ng/ml), pulsed in the last 10 hrs with MART-1 peptide and used as stimulators of purified autologous CD8+T cells. T cell cultures were boosted once at day 7, supplemented with IL-7 and IL-2 and T cell differentiation was assessed by tetramer staining at day 5 after boost. As shown in
Preliminary data on the feasibility of product manufacture and release in patients with metastatic melanoma. To date we have gathered data on product manufacture in 7 patients with stage IV melanoma. These are preliminary results obtained in the course of an ongoing clinical trial (IRB#005-065, IND#12339). These preliminary lot manufacture data using cells from patients with metastatic melanoma who underwent chemotherapy suggest feasibility of the process which was developed using cells from healthy donors as described in prior sections. Sunsequent tables summarize lots manufactured to date using patient's material.
*Due to poor quality of the apheresis product this patient showed monocytes in all fractions post-elutriation. To insure sufficient number of vaccines all fractions were pooled for culture.
This application claims priority to U.S. Provisional Patent Application Ser. No. 60/817,916, Filed Jun. 30, 2006, the entire contents of which are incorporated herein by reference.
This invention was made with U.S. Government support under Contract No. PO1 is 2PO1 CA84512-05A2 and PO1 is 5R01 CA078846-08. The government has certain rights in this invention.
Number | Date | Country | |
---|---|---|---|
60817916 | Jun 2006 | US |